Form 4: Pfizer Executive Vice President Michael McDermott Reports Stock Transactions
SEC Form 4 Filing
Executive Vice President Michael McDermott reports the earn-out of stock appreciation rights and related transactions involving Pfizer common stock.
Summary
- On February 27, 2025, Michael McDermott, an Executive Vice President at Pfizer Inc., reported transactions involving Pfizer's common stock.
- McDermott exercised stock appreciation rights, acquiring 48,419 shares at a price of $31.31.
- He also disposed of 1,108 shares to satisfy tax obligations at $26.1 per share and 45,347 shares to cover the exercise price at $26.06 per share.
- Following these transactions, McDermott directly owns 75,958 shares of Pfizer common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reflecting standard stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, as required by the SEC. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of earliest transaction: earn-out of stock appreciation rights, withholding of shares for tax obligations, and payment of exercise price. |
| 03/03/2025 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.